Shuttle Pharmaceuticals Holdings, Inc.(SHPH)Earnings, Financials & Key Ratios
SHPH•NASDAQ
$0.78
$4M mkt cap·Price updated May 6, 2026
AboutShuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy. Its products in clinical stage include Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and soft tissue sarcomas; and Doranidazole, an injectable hypoxic cell radiation sensitizer for treatment of pancreatic, lung, and liver cancers. The company was founded in 2012 and is based in Rockville, Maryland.Show more
- Revenue$0
- EBITDA-$8M-30.7%
- Net Income-$9M-38.7%
- EPS (Diluted)-885.73-215931.7%
- ROE-383.84%-241.6%
- ROIC-456.38%-33.0%
- Debt/Equity1.65+517.0%
- Interest Coverage-5.66-149.2%
SHPH Key Insights
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Share count reduced 35.1% through buybacks
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Weak momentum: RS Rating 4 (bottom 4%)
- ✗Trading more than 30% below 52-week high
- ✗Expensive at 11.4x book value
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
SHPH Price & Volume
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) stock price & volume — 10-year historical chart
Loading chart...
SHPH Growth Metrics
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-16.53%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-632.47%
Return on Capital
10 Years-642.16%
5 Years-144%
3 Years-144%
Last Year-261.68%
SHPH Peer Comparison
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) competitors in Therapy-focused branded biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SENS | 221.18M | 5.36 | -3.23 | 56.89% | -196.03% | -113.21% | 0.67 | |
 NVCR | 1.88B | 16.50 | -13.52 | 8.28% | -25.66% | -50.82% | 0.85 | |
 AGEN | 137.4M | 3.89 | -1144.12 | 10.37% | 0.1% | |||
 ATNM | 38.68M | 1.24 | -0.98 | -100% | -384.43% | -151.67% | 0.05 | |
 CELC | 6.03B | 139.44 | -49.27 | -179% | 0.85 | |||
 ISRG | 160.44B | 451.73 | 57.40 | 20.51% | 28.15% | 16.89% | 0.02 | |
 RMD | 30.54B | 209.64 | 22.04 | 9.84% | 27.44% | 24.41% | 0.14 | |
 HOLX | 16.97B | 76.01 | 30.53 | 1.74% | 13.18% | 10.37% | 0.52 |
Compare SHPH vs Peers
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SHPH Income Statement
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 18.74K | 18K | 54.95K | 60.83K | 5.97K | 0 | 0 | 2.8K |
| COGS % of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | -18.74K▲ 0% | -18K▲ 3.9% | -54.95K▼ 205.3% | -60.83K▼ 10.7% | -5.97K▲ 90.2% | 0▲ 100.0% | 0▲ 0% | -2.8K▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | 3.94% | -205.28% | -10.71% | 90.18% | 100% | - | - |
| Operating Expenses | 185.15K | 568.63K | 454.57K | 1.68M | 2.34M | 5.89M | 7.7M | 10.9M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 185.99K | 513.06K | 347.75K | 721.18K | 1.29M | 2.38M | 4.08M | 6.37M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - |
| Research & Development | -836 | 55.57K | 161.77K | 1.02M | 1.05M | 3.52M | 3.62M | 4.53M |
| R&D % of Revenue | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | -54.95K | -60.83K | 0 | 0 | 0 | 0 |
| Operating Income | -203.89K▲ 0% | -586.63K▼ 187.7% | -509.52K▲ 13.1% | -1.74M▼ 242.1% | -2.34M▼ 34.5% | -5.89M▼ 151.4% | -7.7M▼ 30.6% | -10.91M▲ 0% |
| Operating Margin % | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -187.72% | 13.14% | -242.08% | -34.47% | -151.4% | -30.61% | - |
| EBITDA | -185.15K | -568.63K | -454.57K | -1.68M | -2.34M | -5.89M | -7.69M | -10.9M |
| EBITDA Margin % | - | - | - | - | - | - | - | - |
| EBITDA Growth % | - | -207.12% | 20.06% | -270.05% | -38.98% | -151.75% | -30.67% | -51.49% |
| D&A (Non-Cash Add-back) | 18.74K | 18K | 54.95K | 60.83K | 5.97K | 6.81K | 5.46K | 3.83K |
| EBIT | -202.71K | -595.22K | -766.1K | -1.1M | -4.33M | -4M | -7.78M | -10.72M |
| Net Interest Income | 0 | 0 | -39.63K | -50.79K | -670.61K | -2.52M | -1.32M | -211.29K |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 79.12K | 38.14K | 570 |
| Interest Expense | 10.88K | 30.92K | 39.63K | 50.79K | 670.61K | 2.6M | 1.36M | 211.86K |
| Other Income/Expense | -9.7K | -39.51K | -296.21K | 590.86K | -2.65M | -700.34K | -1.45M | 200.47K |
| Pretax Income | -213.59K▲ 0% | -626.14K▼ 193.1% | -805.73K▼ 28.7% | -1.15M▼ 43.0% | -5M▼ 333.6% | -6.59M▼ 32.0% | -9.14M▼ 38.7% | -10.71M▲ 0% |
| Pretax Margin % | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -213.59K▲ 0% | -626.14K▼ 193.1% | -805.73K▼ 28.7% | -1.15M▼ 43.0% | -5M▼ 333.6% | -6.59M▼ 32.0% | -9.14M▼ 38.7% | -10.71M▲ 0% |
| Net Margin % | - | - | - | - | - | - | - | - |
| Net Income Growth % | - | -193.14% | -28.68% | -42.99% | -333.64% | -31.96% | -38.71% | -16.53% |
| Net Income (Continuing) | -213.59K | -626.14K | -805.73K | -1.15M | -5M | -6.59M | -9.14M | -10.71M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.02▲ 0% | -0.05▼ 193.6% | -0.07▼ 48.4% | -0.09▼ 38.2% | -0.30▼ 217.5% | -0.41▼ 36.7% | -885.73▼ 215931.7% | -4.79▲ 0% |
| EPS Growth % | - | -193.63% | -48.37% | -38.16% | -217.46% | -36.67% | -215931.71% | -632.47% |
| EPS (Basic) | -0.02 | -0.05 | -0.07 | -0.09 | -0.30 | -0.41 | -885.73 | - |
| Diluted Shares Outstanding | 13.59M | 13.59M | 13.59M | 13.59M | 10.35M | 15.91M | 10.32M | 2.23M |
| Basic Shares Outstanding | 13.59M | 13.59M | 13.59M | 13.59M | 10.35M | 15.91M | 10.32M | 2.23M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
SHPH Balance Sheet
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 102.46K | 613.96K | 341.19K | 509.62K | 8.58M | 5.59M | 2.21M | 3.27M |
| Cash & Short-Term Investments | 50.71K | 352.39K | 117.15K | 504.75K | 8.42M | 5.46M | 1.92M | 2.09M |
| Cash Only | 50.71K | 352.39K | 117.15K | 504.75K | 8.42M | 2.58M | 1.92M | 2.09M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 2.89M | 0 | 0 |
| Accounts Receivable | 49.21K | 3.83K | 211.46K | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 250K | 0 | 0 | 0 | 14.9K | 0 | 0 |
| Total Non-Current Assets | 18.84K | 7.32K | 202.86K | 142.03K | 75.19K | 358.73K | 295.37K | 277.01K |
| Property, Plant & Equipment | 18.84K | 838 | 196.38K | 135.55K | 68.71K | 358.73K | 295.37K | 246.71K |
| Fixed Asset Turnover | - | - | - | - | - | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 6.48K | 6.48K | 6.48K | 6.48K | 0 | 0 | 150.67K |
| Total Assets | 121.3K▲ 0% | 621.27K▲ 412.2% | 544.05K▼ 12.4% | 651.64K▲ 19.8% | 8.65M▲ 1228.0% | 5.95M▼ 31.2% | 2.51M▼ 57.9% | 3.54M▲ 0% |
| Asset Turnover | - | - | - | - | - | - | - | 0.00x |
| Asset Growth % | - | 412.19% | -12.43% | 19.78% | 1227.96% | -31.22% | -57.89% | 475.48% |
| Total Current Liabilities | 405.65K | 593.82K | 2.1M | 2.22M | 975.68K | 1.04M | 1.53M | 1.96M |
| Accounts Payable | 79.1K | 30.73K | 516.97K | 828.31K | 129.25K | 283.31K | 596.6K | 1.47M |
| Days Payables Outstanding | 1.54K | 623.16 | 3.43K | 4.97K | 7.9K | - | - | 134.75K |
| Short-Term Debt | 314.38K | 400K | 686.44K | 849.5K | 685.47K | 596K | 874.48K | 417.52K |
| Deferred Revenue (Current) | 0 | 17.54K | 228.39K | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 12.16K | 145.54K | 386.31K | 94.03K | 0 | 0 | 0 | 0 |
| Current Ratio | 0.25x | 1.03x | 0.16x | 0.23x | 8.79x | 5.37x | 1.44x | 1.44x |
| Quick Ratio | 0.25x | 1.03x | 0.16x | 0.23x | 8.79x | 5.37x | 1.44x | 1.44x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 0 | 129.38K | 62.44K | 0 | 853.73K | 263.37K | 183.86K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 135.09K | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 129.38K | 62.44K | 0 | 304.13K | 238.09K | 828.67K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 414.51K | 25.28K | 67.42K |
| Total Liabilities | 405.65K | 593.82K | 2.23M | 2.28M | 975.68K | 1.9M | 1.8M | 2.15M |
| Total Debt | 314.38K | 400K | 874.28K | 978.88K | 748.3K | 1.09M | 1.17M | 667.33K |
| Net Debt | 263.67K | 47.61K | 757.13K | 474.13K | -7.67M | -1.49M | -746.67K | -1.43M |
| Debt / Equity | - | 14.57x | - | - | 0.10x | 0.27x | 1.65x | 1.65x |
| Debt / EBITDA | - | - | - | - | - | - | - | -0.06x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | 0.13x |
| Interest Coverage | -18.74x | -18.97x | -12.86x | -34.32x | -3.50x | -2.27x | -5.66x | -50.60x |
| Total Equity | -284.35K▲ 0% | 27.46K▲ 109.7% | -1.69M▼ 6256.4% | -1.63M▲ 3.7% | 7.68M▲ 571.6% | 4.06M▼ 47.2% | 709.15K▼ 82.5% | 1.39M▲ 0% |
| Equity Growth % | - | 109.66% | -6256.38% | 3.68% | 571.58% | -47.18% | -82.52% | 492.33% |
| Book Value per Share | -0.02 | 0.00 | -0.12 | -0.12 | 0.74 | 0.25 | 0.07 | 0.62 |
| Total Shareholders' Equity | -284.35K | 27.46K | -1.69M | -1.63M | 7.68M | 4.06M | 709.15K | 1.39M |
| Common Stock | 450K | 179 | 93 | 93 | 136 | 20 | 41 | 13 |
| Retained Earnings | -1.28M | -1.91M | -4.54M | -5.8M | -8.89M | -25.43M | -34.58M | -43.68M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 16.34K | 16.34K | 16.34K | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SHPH Cash Flow Statement
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -202.71K | -566.69K | -26.83K | -300.34K | -2.67M | -5.58M | -7.33M | -7.33M |
| Operating CF Margin % | - | - | - | - | - | - | - | - |
| Operating CF Growth % | - | -179.56% | 95.27% | -1019.36% | -787.81% | -109.31% | -31.29% | -428.39% |
| Net Income | -213.59K | -626.14K | -805.73K | -1.15M | -5M | -6.59M | -9.14M | -10.71M |
| Depreciation & Amortization | 18.74K | 18K | 54.95K | 60.83K | 5.97K | 6.81K | 5.46K | 2.83K |
| Stock-Based Compensation | 0 | 0 | 459.59K | 910.07K | 237.55K | 181.96K | 259.74K | 750.08K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 58.51K | 63.79K | 256.58K | -638.26K | 2.55M | 602.17K | 1.41M | -298.78K |
| Working Capital Changes | -9.03K | 16.65K | 7.78K | 519.15K | -462.79K | 220.63K | 138.91K | -947.68K |
| Change in Receivables | -30.43K | 45.38K | 164.93K | 211.46K | 0 | -14.9K | 14.9K | 4 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 10.58K | -48.37K | -51.13K | 311.35K | -370.38K | 154.06K | 313.3K | 124.45K |
| Cash from Investing | 0 | 0 | -10.82K | 0 | 0 | -2.83M | 2.92M | 0 |
| Capital Expenditures | 0 | 0 | -10.82K | 0 | 0 | -19.05K | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 160.62K | 868.37K | 70.07K | 687.93K | 10.58M | 2.57M | 3.76M | 13.14M |
| Debt Issued (Net) | 160.52K | 205.87K | 70.07K | 687.93K | 600.72K | 3.25M | 133.46K | 505.75K |
| Equity Issued (Net) | 100 | 912.5K | 0 | 0 | 1000K | 0 | 1000K | 2.97M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | -250K | 0 | 0 | -17.36K | -679.44K | -370.95K | -209.09K |
| Net Change in Cash | -42.09K▲ 0% | 301.68K▲ 816.8% | 32.42K▼ 89.3% | 387.6K▲ 1095.4% | 7.91M▲ 1941.4% | -5.84M▼ 173.8% | -656.27K▲ 88.8% | 1.94M▲ 0% |
| Free Cash Flow | -202.71K▲ 0% | -566.69K▼ 179.6% | -37.65K▲ 93.4% | -300.34K▼ 697.7% | -2.67M▼ 787.8% | -5.6M▼ 110.0% | -7.33M▼ 30.8% | -11.2M▲ 0% |
| FCF Margin % | - | - | - | - | - | - | - | - |
| FCF Growth % | - | -179.56% | 93.36% | -697.73% | -787.81% | -110.03% | -30.84% | -96.5% |
| FCF per Share | -0.01 | -0.04 | -0.00 | -0.02 | -0.26 | -0.35 | -0.71 | -0.71 |
| FCF Conversion (FCF/Net Income) | 0.95x | 0.91x | 0.03x | 0.26x | 0.53x | 0.85x | 0.80x | 1.05x |
| Interest Paid | 0 | 0 | 1.89K | 293 | 39.2K | 164.81K | 86.59K | 36.15K |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SHPH Key Ratios
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -2280.52% | - | - | -165.17% | -112.37% | -383.84% | -476.1% |
| Return on Invested Capital (ROIC) | -1617.96% | - | - | - | -343.11% | -456.38% | -456.38% |
| Debt / Equity | 14.57x | - | - | 0.10x | 0.27x | 1.65x | 1.65x |
| Interest Coverage | -18.97x | -12.86x | -34.32x | -3.50x | -2.27x | -5.66x | -50.60x |
| FCF Conversion | 0.91x | 0.03x | 0.26x | 0.53x | 0.85x | 0.80x | 1.05x |
SHPH Frequently Asked Questions
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) grew revenue by 0.0% over the past year. Growth has been modest.
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) reported a net loss of $10.7M for fiscal year 2024.
Dividend & Returns
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) has a return on equity (ROE) of -383.8%. Negative ROE indicates the company is unprofitable.
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) had negative free cash flow of $11.2M in fiscal year 2024, likely due to heavy capital investments.
Explore More SHPH
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates